Fundamentals Hub
NIKI Niki BioSolutions, Inc.
NIKI financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 8 annual and 0 of 0 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Other
Industry (SIC)
3829 Measuring & Controlling Devices, NEC
Incorporated
E9
Fiscal Year End
December (1231)
Phone
852 3953 7700
EIN
000000000
Headquarters
PRINCETON, NJ, 08540
Former Names:
Aptorum Group Ltd (2018–2026)
▼ Key Metrics (FY 2025)
As of Dec 31, 2025Financials
Revenue
-
Net Income
$-1.36M
Total Assets
$18.69M
Total Equity
$13.74M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-9.9%
Return on Assets
-7.3%
Current Ratio
0.78x
EPS Growth (YoY)
75.6%
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | - | - | $431.38K |
| Cost of Revenue | - | - | $420.81K |
| Gross Profit | - | - | $10.57K |
| OPERATING EXPENSES | |||
| R&D Expense | $352.88K | $2.20M | $5.20M |
| SG&A Expense | $573.06K | $669.49K | $1.93M |
| NON-OPERATING INCOME / EXPENSE | |||
| Other Income/Expense | $441.10K | $-217.20K | $6.38M |
| Pretax Income | $-1.38M | $-4.16M | $-4.34M |
| Net Income | $-1.36M | $-4.27M | $-2.82M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.19 | $-0.78 | $-0.62 |
| Diluted Shares | 7.35M | 5.45M | 4.52M |
| Depreciation & Amortization | - | $255.05K | $1.13M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $3.45M | $874.24K | $2.01M |
| Accounts Receivable | - | - | $47.71K |
| Other Current Assets | $139.63K | $85.32K | $422.07K |
| Current Assets | $3.59M | $959.55K | $2.48M |
| PP&E (Net) | - | - | $1.66M |
| Intangible Assets | - | - | $147.35K |
| Noncurrent Assets | $15.10M | $15.17M | $18.16M |
| Total Assets | $18.69M | $16.13M | $20.64M |
| LIABILITIES | |||
| Accounts Payable | $1.07M | $918.61K | $1.89M |
| Current Liabilities | $4.59M | $4.34M | $2.10M |
| Noncurrent Liabilities | $306.00K | $14.18K | $3.16M |
| Total Liabilities | $4.90M | $4.35M | $5.26M |
| EQUITY | |||
| Additional Paid-in Capital | $97.00M | $93.47M | $93.02M |
| Retained Earnings | $-73.79M | $-72.43M | $-68.16M |
| Accumulated OCI | $-92.31K | $89.16K | $-10.62K |
| Total Equity | $13.74M | $11.78M | $15.38M |
| Temporary Equity | $47.00K | - | - |
| Total Liabilities & Equity | $18.69M | $16.13M | $20.64M |
| SUPPLEMENTAL | |||
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-1.84M | $-1.19M | $-7.72M |
| Capital Expenditures | - | - | $3.02K |
| Cash from Investing | $0 | $58.62K | $624.77K |
| Cash from Financing | $4.42M | $0 | $4.09M |
| Free Cash Flow | - | - | $-7.73M |
| Beginning Cash (CFS) | $874.24K | $2.01M | $5.01M |
| Net Change in Cash | $2.58M | $-1.13M | $-3.01M |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $3.45M | $874.24K | $2.01M |
| Cash per BS | $3.45M | $874.24K | $2.01M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $3.45M | $874.24K | $2.01M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Niki BioSolutions, Inc. profitable?
No. Niki BioSolutions, Inc. reported $-1.36M in net income for fiscal year 2025. Profitability data is based on the company's most recent annual report filed with the SEC.